Results 111 to 120 of about 108,380,509 (205)

Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the responce in the forced swim test and on monoamine extracellulars levels in the frontal cortex of the mouse.

, 2003
We tested fluoxetine, bupropion and GR 205171, a selective neurokinin-1 receptor antagonist on forced swimming test (FST) response and on levels of monoamines in frontal cortex of CD1 mice by microdialysis techniques. All drugs decreased immobility time.
Gerrard P. A., Zocchi A., Varnier G., Griffante C., Arban R., Corsi M., Bettelini L., Marchi M., ZANETTI, LARA   +8 more
core   +1 more source

The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia. [PDF]

J Clin Med, 2020
Muñoz M, Coveñas R.
europepmc   +1 more source

In Silico Study of Neurokinin-1 Receptor Antagonists by QSAR Modeling

, 2017
QSAR studies were performed on a series neurokinin-1 receptor. neurokinin-1 receptor have been analyzed in relation to their physicochemical and molecular properties. On the basis of QSAR studies presented here, the coefficients of Id, IOR, MR, MW, ST, MV, Pz are positive and therefore it may be suggested that denser, bulkier, more polar substituents ...
openaire   +2 more sources

The Effects of Serotonin Receptor Antagonists on Contraction and Relaxation Responses Induced by Electrical Stimulation in the Rat Small Intestine [PDF]

, 2014
Background: The main source of 5-HT in body is in enterchromafin cells of intestine, different studies mentioned different roles for endogenous 5-HT and receptors involved and it is not clearified the mechanism of action of endogenous 5-HT. Objectives:
Javid, Farideh A., Mashhadi, Farzaneh Farajian, Naylor, Robert J.   +2 more
core   +1 more source

Synthesis and neurokinin antagonist activity of 2-benzylidene- and 2- benzyl-3-benzylamino quinuclidines

, 1993
Molecular modeling studies based on the potent NK-1 antagonist CP-96,345 led us to the identification of some 2-benzylidene- and 2-benzyl-3- benzylaminoquinuclidine derivatives as potential antagonists at the NK receptor subtypes.
Santini A., Vittoria A., GRECO, GIOVANNI, Turbanti L., SANTAGADA, VINCENZO, Renzetti A. R., CALIENDO, GIUSEPPE, Pedone C., PERISSUTTI, ELISA, Benedetti E., Silipo C.   +10 more
core  

Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy. [PDF]

BMJ Open, 2020
Minatogawa H, Izawa N, Kawaguchi T, Miyaji T, Shimomura K, Kazunori H, Iihara H, Ohno Y, Inada Y, Arioka H, Morita H, Hida N, Sugawara M, Katada C, Nawata S, Ishida H, Tsuboya A, Tsuda T, Yamaguchi T, Nakajima TE.   +19 more
europepmc   +1 more source

Aprepitant, a Neurokinin-1 Receptor Antagonist, as a Disruptive Drug for the Treatment of Pediatric Cancer. [PDF]

J Clin Med
Rosso M, Alcaide C, Muñoz M.
europepmc   +1 more source

Patient factors and costs associated with prophylactic neurokinin-1 receptor antagonist use among women with invasive breast cancer. [PDF]

J Manag Care Spec Pharm
Kamat S, Brown BR, Cohen SA, Vyas A.
europepmc   +1 more source

Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma. [PDF]

Cancers (Basel)
Muñoz M, Rosso M.
europepmc   +1 more source

Comment on "Dexamethasone-sparing on days 2-4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)". [PDF]

Br J Cancer
Celio L, Antonuzzo A, Aapro MS.
europepmc   +1 more source